Sunday, November 15, 2026

Peer-Reviewed Clinical Evidence Platform

The research that matters, without the jargon.

Peer-reviewed breakthroughs in plain English alongside verified outcomes, evidence grades, and clinical study details for everyone from everyday readers to medical students.

ClearMed Editorial Digest500 briefings across 12 specialties121 Phase III & clinical practice

Indexed from PubMed, NEJM, The Lancet, JAMA, Nature MedicineSaved Library

Health Hubs:

Stage: Evidence:

Showing 30 briefings matching “kidney”

Reset all filters

Nephrology

Nephrology Clinical Briefings

Peer-Reviewed Clinical Digests · Verified Scientific Media

NEPHROLOGY · PRECLINICAL

Gut-targeted interventions to complement PTH-lowering therapy

These findings highlight the potential of gut-targeted interventions to complement established parathyroid hormone-lowering strategies for improving skeletal health. Secondary hyperparathyroidism is a major contributor to skeletal fragility in chronic kidney disease, yet fracture risk remains high despite parathyroid hormone-lowering therapy.

2/5 Preclinical

Evidence Meter · 2/5

Animal & Preclinical Data

Demonstrated in living animal models before large-scale human safety and dosing trials begin.

1 min readKidney InternationalNov 15, 2026

NEPHROLOGY · PHASE I/II

Fingerprinting the polycystic kidney: radiomics of the noncystic parenchyma for earlier ADPKD detection

Small, cross-sectional, unmatched data require longitudinal validation of reproducibility, prognostic value, and clinical utility. Autosomal dominant polycystic kidney disease risk stratification relies on total kidney volume, a validated marker of cyst burden and progression.

3/5 Observational

Evidence Meter · 3/5

Real-World Observation

Finds meaningful patterns in human health records or cohorts, though observational data cannot prove direct cause.

1 min readKidney InternationalNov 15, 2026

NEPHROLOGY · CLINICAL PRACTICE

Kidney stone disease: to drink or not to drink-that is the question

Effective prevention likely requires achieving a substantial increase in urine volume alongside comprehensive dietary and pharmacologic management. An important point to note is that these findings do not invalidate the protective role of increased urine volume but highlight the limitations of behavioral interventions alone.

3/5 Observational

Evidence Meter · 3/5

Real-World Observation

Finds meaningful patterns in human health records or cohorts, though observational data cannot prove direct cause.

1 min readKidney InternationalNov 15, 2026

NEPHROLOGY · CLINICAL PRACTICE

The macrophage paradox in renal AL amyloidosis: lessons from histology and imaging

These findings offer insights into the mechanisms of renal involvement and highlight the complex, context-dependent role of macrophages in amyloid clearance and tissue injury. In renal amyloid light chain amyloidosis, sustained and deep hematologic response drives organ response that continues to improve over time.

3/5 Observational

Evidence Meter · 3/5

Real-World Observation

Finds meaningful patterns in human health records or cohorts, though observational data cannot prove direct cause.

1 min readKidney InternationalNov 15, 2026

NEPHROLOGY · REAL-WORLD COHORT

Estimating GFR: what it is, what it is not, and why prediction cannot settle the question

Equations are population tools; at the bedside, non-glomerular filtration rate determinants of both creatinine and cystatin C can mislead. Schultheiss et al. show that replacing Chronic Kidney Disease Epidemiology Collaboration with European Kidney Function Consortium cystatin C-based equations reclassifies women, but not men, into milder chronic kidney disease stages, while outcome prediction is unchanged.

3/5 Observational

Evidence Meter · 3/5

Real-World Observation

Finds meaningful patterns in human health records or cohorts, though observational data cannot prove direct cause.

1 min readKidney InternationalNov 15, 2026

NEPHROLOGY · REAL-WORLD COHORT

Fetal growth restriction and lifelong risk of acute kidney injury: advancing the developmental origins of kidney disease

We examine the study's strengths, limitations, biological basis, and clinical relevance, highlighting opportunities for targeted risk stratification, preventive care, and future research. Fetal growth restriction has long been associated with reduced nephron number and chronic kidney disease, but its relationship with acute kidney injury has remained unclear.

3/5 Observational

Evidence Meter · 3/5

Real-World Observation

Finds meaningful patterns in human health records or cohorts, though observational data cannot prove direct cause.

1 min readKidney InternationalNov 15, 2026

NEPHROLOGY · REAL-WORLD COHORT

Applicability of Prediction Models: Aligning Models with Clinical Use

This review offers practical steps to keep predictions aligned with the patients they serve. Using severe chronic kidney disease as an example, this review shows that a model built from patients who have recently progressed to this more severe stage works better for patients at that same point, while a model built from patients who have lived with the disease for years works better for those further along.

3/5 Observational

Evidence Meter · 3/5

Real-World Observation

Finds meaningful patterns in human health records or cohorts, though observational data cannot prove direct cause.

1 min readKidney InternationalNov 12, 2026

NEPHROLOGY · REAL-WORLD COHORT

Pooled cohort analysis of renin-angiotensin system inhibition and the risk of kidney outcomes in APOL1-mediated chronic kidney disease in the CRIC and SPRINT studies

RASi-based therapy, addressed as a time-updated pooled treatment, provided similar benefit across APOL1 genotypes, driven by albuminuric participants. Among individuals with two APOL1 risk alleles, outcomes were similar regardless of baseline albuminuria.

3/5 Observational

Evidence Meter · 3/5

Real-World Observation

Finds meaningful patterns in human health records or cohorts, though observational data cannot prove direct cause.

1 min readKidney InternationalNov 12, 2026

NEPHROLOGY · PRECLINICAL

Metabolic Unloading: How SGLT2i Recalibrate Cell Energetics to Slow CKD Progression

This review positions cellular energetics as an important upstream constraint shaping kidney disease progression, offering a foundation for nephroprotective strategies. This framework integrates spatial cortex-medulla vulnerability, reconciles early hemodynamic changes with durable slowing of estimated glomerular filtration rate decline, and explores disease-agnostic benefit.

2/5 Preclinical

Evidence Meter · 2/5

Animal & Preclinical Data

Demonstrated in living animal models before large-scale human safety and dosing trials begin.

1 min readKidney InternationalNov 11, 2026

NEPHROLOGY · CLINICAL PRACTICE

Abnormal ER-Golgi vesicular trafficking leads to podocyte detachment

These findings establish, for the first time, a critical role for endoplasmic reticulum-to-Golgi vesicular trafficking in maintaining podocyte integrity. Podocyte detachment represents a point of no return in the progression of proteinuric kidney diseases, yet the molecular mechanisms driving this process remain poorly understood.

3/5 Observational

Evidence Meter · 3/5

Real-World Observation

Finds meaningful patterns in human health records or cohorts, though observational data cannot prove direct cause.

1 min readKidney InternationalNov 11, 2026

NEPHROLOGY · PRECLINICAL

Are we ready for the widespread application of transcutaneous measurement of the glomerular filtration rate?

The observations by Shimada et al. highlight both the promise and limitations of transcutaneous glomerular filtration rate, particularly in conditions that affect distribution volume, underscoring the need for rigorous evaluation across diverse physiological and disease states. Accurate assessment of glomerular filtration rate is central to renal evaluation in clinical and preclinical settings.

2/5 Preclinical

Evidence Meter · 2/5

Animal & Preclinical Data

Demonstrated in living animal models before large-scale human safety and dosing trials begin.

1 min readKidney InternationalNov 10, 2026

NEPHROLOGY · CLINICAL PRACTICE

Microvascular inflammation in kidney transplants: finally an effective treatment?

As demonstrated in a study in this issue of Kidney International, targeting CD38, a glycoprotein expressed on both plasma cells and natural killer cells, shows great promise in treating microvascular inflammation in kidney transplants. Microvascular inflammation-glomerulitis and peritubular capillaritis-is the hallmark histologic lesion of antibody-mediated allograft rejection and may also occur in the absence of donor-specific antibodies.

3/5 Observational

Evidence Meter · 3/5

Real-World Observation

Finds meaningful patterns in human health records or cohorts, though observational data cannot prove direct cause.

1 min readKidney InternationalNov 8, 2026

Showing 12 of 30 medical briefings

Interactive Fact Check